China’s Sinovac Biotech has secured $515m in funding to double the production capacity of its coronavirus vaccine, it said on Monday, with efficacy data on its experimental medicine due this month. Al Jazeera reports that the firm said in a separate statement that it is currently able to manufacture 300 million vaccine doses annually and aims to complete construction of a second production facility by the end of the year to increase annual production capacity to 600 million doses. The company has also already signed supply deals with several countries including Indonesia, Turkey, Brazil, and Chile and is holding talks with the Philippines for a potential sale.